Axsome Therapeutics Inc’s recently made public that its Chief Executive Officer TABUTEAU HERRIOT unloaded Company’s shares for reported $7.12 million on Dec 02 ’25. In the deal valued at $144.59 per share,49,252 shares were sold. As a result of this transaction, TABUTEAU HERRIOT now holds 7,229 shares worth roughly $1.08 million.
Then, TABUTEAU HERRIOT sold 20,163 shares, generating $2,962,751 in total proceeds. Upon selling the shares at $146.94, the Chief Executive Officer now owns 7,229 shares.
Before that, TABUTEAU HERRIOT sold 10,558 shares. Axsome Therapeutics Inc shares valued at $1,564,484 were divested by the Chief Executive Officer at a price of $148.18 per share. As a result of the transaction, TABUTEAU HERRIOT now holds 7,229 shares, worth roughly $1.08 million.
B. Riley Securities initiated its Axsome Therapeutics Inc [AXSM] rating to a Buy in a research note published on October 01, 2025; the price target was $179. Oppenheimer started covering the stock on June 03, 2025. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock fall -1.25% to $148.79. Over the last five days, the stock has lost -3.82%. Axsome Therapeutics Inc shares have risen nearly 69.14% since the year began. Nevertheless, the stocks have risen 75.85% over the past one year. While a 52-week high of $158.56 was reached on 12/23/25, a 52-week low of $75.56 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 146.94, which if violated will result in even more drops to 145.10. On the upside, there is a resistance level at 151.83. A further resistance level may holdings at 154.87.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-12-15, dropping by -0.56 million shares to a total of 2.84 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 3.39 million shares. There was a decline of -19.68%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 07, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $200 price target.
